EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer comparing 6 cycles of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel administrations First safety analysis of GEICAM 9906 Trial



Multicenter, randomized phase III study of adjuvant chemotherapy for axillary positive breast cancer comparing 6 cycles of FEC vs 4 cy of FEC followed by 8 weekly paclitaxel administrations First safety analysis of GEICAM 9906 Trial



Breast Cancer Research & Treatment 82(Supplement 1): S29-S30




(PDF 0-2 workdays service: $29.90)

Accession: 035349984

Download citation: RISBibTeXText



Related references

Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing tac with fac: 5-year efficacy analysis of the GEICAM 9805 trial. Journal of Clinical Oncology 26(15_suppl): 542-542, 2016

Neoadjuvant Therapy with Weekly Nanoparticle Albumin-Bound Paclitaxel for Luminal Early Breast Cancer Patients: Results from the NABRAX Study (GEICAM/2011-02), a Multicenter, Non-Randomized, Phase II Trial, with a Companion Biomarker Analysis. Oncologist 22(11): 1301-1308, 2017

Upregulation of HER-2/neu is independent of the menopausal status of primary breast cancer patients: Plasma results from a prospectively randomized trial comparing dose-intense chemotherapy with G-CSF support to 3-weekly chemotherapy for adjuvant therapy of nodal-positive (1-3 LN) breast cancer (German Adjuvant Study Group ASG). Journal of Clinical Oncology 23(16_suppl): 638-638, 2016

Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. Journal of Clinical Oncology 21(2): 298-305, 2003

Randomized phase III trial comparing the sequential administration of docetaxel followed by epirubicin plus cyclophosphamide versus FE 75 C as adjuvant chemotherapy in axillary lymph node-positive breast cancer. Journal of Clinical Oncology 26(15_suppl): 521-521, 2016

Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Annals of Oncology 15(1): 79-87, 2003

Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study. Annals of Oncology 15(1): 79-87, 2004

Results of her-2/neu, EGFR and CA2729 in serum in a randomized trial comparing biweekly epirubicin followed by paclitaxel with G-csf support to 3-weekly epirucibin plus cyclophosphamide followed by paclitaxel for adjuvant therapy of nodal-positive breast cancer. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1270, July, 2003

Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG). Breast Cancer Research and Treatment 148(3): 591-597, 2015

WSG/AGO-Mamma Phase III Trial First toxicity analysis of a German intergroup study for patients with primary breast cancer and 1-3 positive axillary lymph nodes Comparison of six cycles FEC or CMF chemotherapy with four cycles EC followed by four cycles of docetaxel. Breast 12(Supplement 1): S45, February, 2003

Safety analysis of the PACS 01 adjuvant trial comparing 6 cycles of FEC 100 to 3 cycles of FEC 100 followed by 3 cycles of docetaxel Taxotere for node positive breast cancer. Breast Cancer Research & Treatment 82(Supplement 1): S32, 2003

Randomized Multicenter Phase II Trial of Neoadjuvant Therapy Comparing Weekly Nab-paclitaxel Followed by FEC With Docetaxel Followed by FEC in HER2- Early-stage Breast Cancer. Clinical Breast Cancer, 2018

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. Journal of Clinical Oncology 22(13): 2587-2593, 2004

Longitudinal serum results of HER-2/neu, EGFR and CA2729 in a randomized trial comparing dose-intense, biweekly epirubicin followed by paclitaxel to 3-weekly epirubicin plus cyclophosphamide followed by paclitaxel for adjuvant therapy of nodal-positive breast cancer. Breast Cancer Research & Treatment 82(Supplement 1): S130, 2003

Randomized, multicenter, crossover phase II trial to compare exemestane (E) vs. anastrozole (A) in postmenopausal patients (pt) with advanced breast cancer (ABC) and positive hormone receptors (HR). Final efficacy analysis of GEICAM 2001-03 study. Journal of Clinical Oncology 24(18_suppl): 638-638, 2016